» Articles » PMID: 17230520

Differential Involvement of Reactive Oxygen Species in Apoptosis Induced by Two Classes of Selenium Compounds in Human Prostate Cancer Cells

Overview
Journal Int J Cancer
Specialty Oncology
Date 2007 Jan 19
PMID 17230520
Citations 34
Authors
Affiliations
Soon will be listed here.
Abstract

Selenium is a promising chemopreventive agent for prostate cancer, possibly via an induction of apoptosis. Earlier studies have shown that selenite induces DNA single strand breaks (SSBs), reactive oxygen species (ROS), p53 Ser-15 phosphorylation and caspase-dependent and -independent apoptosis, whereas a methylselenol precursor methylseleninic acid (MSeA) induces caspase-mediated apoptosis regardless of p53 status. Here we address three main questions: What types of ROS are induced by selenite vs. MSeA in LNCaP (p53 wild type, androgen-responsive) and DU145 (mutant p53, androgen-independent) prostate cancer cells? Does ROS generation depend on androgen signaling? What are the relationships among ROS, DNA SSBs, p53 and caspases? We show that selenite (5 microM) induced superoxide and hydrogen peroxide in LNCaP cells much more than in DU145 cells and the ROS generation was not affected by physiological androgen stimulation. MSeA (10 microM) induced apoptosis without either type of ROS in both cell lines. In LNCaP cells, we established superoxide as a primary mediator for selenite-induced DNA SSBs, p53 activation and caspase-mediated apoptosis. Furthermore a p53-dominant negative mutant attenuated selenite-induced ROS, leading to a proportionate protection against apoptosis. The results support the p53-mitochondria axis in a feedback loop for sustaining superoxide production to lead to efficient caspase-mediated apoptosis by selenite. In contrast, caspase-mediated apoptosis induced by MSeA does not involve ROS induction. Since p53 is frequently mutated or deleted in prostate cancer and many other cancers, our results suggest that genotoxic vs. nongenotoxic classes of selenium may exert differential apoptosis efficacy depending on the p53 status of the cancer cells.

Citing Articles

assembly and characterization of the transcriptome of growth with selenium supplementation.

Du M, Huang S, Huang Z, Qian L, Gui Y, Hu J PeerJ. 2024; 12:e17426.

PMID: 38832042 PMC: 11146319. DOI: 10.7717/peerj.17426.


Potential New Therapies "ROS-Based" in CLL: An Innovative Paradigm in the Induction of Tumor Cell Apoptosis.

Sciaccotta R, Gangemi S, Penna G, Giordano L, Pioggia G, Allegra A Antioxidants (Basel). 2024; 13(4).

PMID: 38671922 PMC: 11047475. DOI: 10.3390/antiox13040475.


Combination of Selenite and Butyrate Enhances Efficacy Against Colon Cancer by Targeting ASCT2-Mediated Amino Acid Metabolism.

Cui J, Li J, Zhao S, Fan L, Yin S, Zhao C Biol Trace Elem Res. 2023; 202(8):3565-3573.

PMID: 37897593 DOI: 10.1007/s12011-023-03927-2.


Differential Inhibition of Anaplerotic Pyruvate Carboxylation and Glutaminolysis-Fueled Anabolism Underlies Distinct Toxicity of Selenium Agents in Human Lung Cancer.

W-M Fan T, Winnike J, Al-Attar A, Belshoff A, Lorkiewicz P, Tan J Metabolites. 2023; 13(7).

PMID: 37512481 PMC: 10383978. DOI: 10.3390/metabo13070774.


Mycochemistry, antioxidant content, and antioxidant potentiality of the ethanolic extract of and its anti-cancerous effect on HeLa cancer cell line, and antitumor effect on HeLa-implanted mice.

Pandey K, Ghosh S, Sanyal T, Bera T, Pal S Int J Health Sci (Qassim). 2023; 17(1):18-35.

PMID: 36704494 PMC: 9832905.